Sorafenib alone versus Sorafenib combined with Gemcitabine and Oxaliplatin (GEMOX) in the first-line treatment of advanced hepatocellular carcinoma: final analysis of the randomized phase II GoNext trial (a UNICANCER/FFCD/PRODIGE 10 study)

被引：0
|
作者：
Assenat, E. [1 ]
Boige, V. [2 ]
Thezenas, S. [3 ]
Pageaux, G. P. [4 ]
Perron, J. M. [5 ]
Becouarn, Y. [6 ]
Seitz, J. F. [7 ]
Merle, P. H. [8 ]
Blanc, J. F. [9 ]
Ychou, M. [10 ]
机构：
[1] Univ Hosp Montpellier, Montpellier 05, France
[2] IGR Canc Ctr, Villejuif, France
[3] ICM Canc Ctr, Montpellier, France
[4] CHU St Eloi, Montpellier, France
[5] CHU, Toulouse, France
[6] Inst Bergonier, Bordeaux, France
[7] CHU La Timone, Marseille, France
[8] CHU, Lyon, France
[9] CHU St Andre, Bordeaux, France
[10] ICM Canc Ctr, Montpellier, France
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2467
引用
收藏
页码：S578 / S578
页数：1
相关论文
共 50 条
  • [41] Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis
    Kim, John J.
    McFarlane, Thomas
    Tully, Stephen
    Wong, William W. L.
    ONCOLOGIST, 2020, 25 (03): : E512 - E519
  • [42] Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients
    Tak, Won Young
    Ryoo, Baek-Yeol
    Lim, Ho Yeong
    Kim, Do-Young
    Okusaka, Takuji
    Ikeda, Masafumi
    Hidaka, Hisashi
    Yeon, Jong-Eun
    Mizukoshi, Eishiro
    Morimoto, Manabu
    Lee, Myung-Ah
    Yasui, Kohichiroh
    Kawaguchi, Yasunori
    Heo, Jeong
    Morita, Sojiro
    Kim, Tae-You
    Furuse, Junji
    Katayama, Kazuhiro
    Aramaki, Takeshi
    Hara, Rina
    Kimura, Takuya
    Nakamura, Osamu
    Kudo, Masatoshi
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1072 - 1084
  • [43] Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients
    Won Young Tak
    Baek-Yeol Ryoo
    Ho Yeong Lim
    Do-Young Kim
    Takuji Okusaka
    Masafumi Ikeda
    Hisashi Hidaka
    Jong-Eun Yeon
    Eishiro Mizukoshi
    Manabu Morimoto
    Myung-Ah Lee
    Kohichiroh Yasui
    Yasunori Kawaguchi
    Jeong Heo
    Sojiro Morita
    Tae-You Kim
    Junji Furuse
    Kazuhiro Katayama
    Takeshi Aramaki
    Rina Hara
    Takuya Kimura
    Osamu Nakamura
    Masatoshi Kudo
    Investigational New Drugs, 2018, 36 : 1072 - 1084
  • [44] Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis
    Casadei-Gardini, Andrea
    Scartozzi, Mario
    Tada, Toshifumi
    Yoo, Changhoon
    Shimose, Shigeo
    Masi, Gianluca
    Lonardi, Sara
    Frassineti, Luca Giovanni
    Nicola, Silvestris
    Piscaglia, Fabio
    Kumada, Takashi
    Kim, Hyung-Don
    Koga, Hironori
    Vivaldi, Caterina
    Solda, Caterina
    Hiraoka, Atsushi
    Bang, Yeonghak
    Atsukawa, Masanori
    Torimura, Takuji
    Tsuj, Kunihiko
    Itobayashi, Ei
    Toyoda, Hidenori
    Fukunishi, Shinya
    Rimassa, Lorenza
    Rimini, Margherita
    Cascinu, Stefano
    Cucchetti, Alessandro
    LIVER INTERNATIONAL, 2021, 41 (06) : 1389 - 1397
  • [45] Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis
    Rizzo, Alessandro
    Carloni, Riccardo
    Ricci, Angela Dalia
    Cusmai, Antonio
    Laforgia, Mariarita
    Calabro, Concetta
    Ungaro, Valentina
    Oreste, Donato
    Sollitto, Mario
    Palmiotti, Gennaro
    Brandi, Giovanni
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (04) : 323 - 329
  • [46] Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Facciorusso, Antonio
    Tartaglia, Nicola
    Villani, Rosanna
    Serviddio, Gaetano
    Ramai, Daryl
    Mohan, Babu P.
    Chandan, Saurabh
    Abd El Aziz, Mohamed A.
    Evangelista, Jessica
    Cotsoglou, Christian
    Ambrosi, Antonio
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (04): : 2379 - 2387
  • [47] Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Phase 3 CALGB 80802 Randomized Clinical Trial
    Abou-Alfa, Ghassan K.
    Shi, Qian
    Knox, Jennifer J.
    Kaubisch, Andreas
    Niedzwiecki, Donna
    Posey, James
    Tan, Benjamin R., Jr.
    Kavan, Petr
    Goel, Rakesh
    Lammers, Philip E.
    Bekaii-Saab, Tanios S.
    Tam, Vincent C.
    Rajdev, Lakshmi
    Kelley, Robin K.
    El Dika, Imane
    Zemla, Tyler
    Potaracke, Ryan, I
    Balletti, Jennifer
    El-Khoueiry, Anthony B.
    Harding, James H.
    Suga, Jennifer M.
    Schwartz, Lawrence H.
    Goldberg, Richard M.
    Bertagnolli, Monica M.
    Meyerhardt, Jeffrey
    O'Reilly, Eileen M.
    Venook, Alan P.
    JAMA ONCOLOGY, 2019, 5 (11) : 1582 - 1588
  • [48] Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
    Qin, Shukui
    Bi, Feng
    Gu, Shanzhi
    Bai, Yuxian
    Chen, Zhendong
    Wang, Zishu
    Ying, Jieer
    Lu, Yinying
    Meng, Zhiqiang
    Pan, Hongming
    Yang, Ping
    Zhang, Helong
    Chen, Xi
    Xu, Aibing
    Cui, Chengxu
    Zhu, Bo
    Wu, Jian
    Xin, Xiaoli
    Wang, Jufeng
    Shan, Jinlu
    Chen, Junhui
    Zheng, Zhendong
    Xu, Li
    Wen, Xiaoyu
    You, Zhenyu
    Ren, Zhenggang
    Liu, Xiufeng
    Qiu, Meng
    Wu, Liqing
    Chen, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (27) : 3002 - +
  • [49] Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
    Kudo, Masatoshi
    Finn, Richard S.
    Qin, Shukui
    Han, Kwang-Hyub
    Ikeda, Kenji
    Piscaglia, Fabio
    Baron, Ari
    Park, Joong-Won
    Han, Guohong
    Jassem, Jacek
    Blanc, Jean Frederic
    Vogel, Arndt
    Komov, Dmitry
    Evans, T. R. Jeffry
    Lopez, Carlos
    Dutcus, Corina
    Guo, Matthew
    Saito, Kenichi
    Kraljevic, Silvija
    Tamai, Toshiyuki
    Ren, Min
    Cheng, Ann-Lii
    LANCET, 2018, 391 (10126): : 1163 - 1173
  • [50] Gemcitabine and oxaliplatin (GEMOX) alone or with cetuximab in first-line treatment of advanced biliary cancers (ABC): Exploratory analyses according to tumor KRAS/BRAF mutations and EGFR expression in a randomized phase II trial (BINGO)
    Malka, David
    Cervera, Pascale
    Heurteau-Foulon, Stephanie
    Wendum, Dominique
    Trarbach, Tanja
    De La Fouchardiere, Christelle
    Boucher, Eveline
    Fartoux, Laetitia
    Faivre, Sandrine J.
    Pignon, Jean-Pierre
    Rosmorduc, Olivier
    Greten, Tim F.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345